Loading…

Lanxess AGLXS.DECompetitor analysis, valuation and peers

Germany · EUR·Materials›Chemicals: Major Diversified

German specialty-chemicals company making additives, industrial intermediates and consumer-protection chemicals, spun off from Bayer.

≈ A German specialty-chemicals peer to Ashland/AlbemarleMomentum weak 32
Mkt cap
$1.19B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$9.70M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-5.8 pp
WACC 5.5%
Hurdle
+7 pp
Req g minus delivered
Official | Implied
NR / BB-
agencies · bond market
Next earnings
119 days
17 Mar 2027
Close · EUR€12.55
1D-0.6%
1W-2.9%
1M+1.4%
3M-9.5%
6M-24.4%
YTD-28.8%
1Y-23.5%
ATR %4.4%
52w lowhigh43.0% off high

What Lanxess does

German specialty-chemicals company making additives, industrial intermediates and consumer-protection chemicals, spun off from Bayer.

Sells specialty chemicals to industrial customers, with Europe the home base. In 2023 it put its engineering-plastics business into Envalior, a joint venture with the investor Advent in which it kept a minority stake; its 2026 sale attempt fell through, with later windows in 2027 and 2028. It has been shifting toward consumer-related products.

In one line: A German specialty-chemicals peer to Ashland/Albemarle.

Products and services

  • Specialty Additives (rubber, plastics, flame retardants, lub
  • Advanced Industrial Intermediates (fine chemicals, pigments)
  • Consumer Protection (disinfectants, preservatives, flavors a
  • Minority stake in Envalior (engineering-plastics JV with Adv

Customers

  • Tire and rubber makers
  • Paint, plastics and construction-materials makers
  • Agrochemical, pharma and hygiene customers

Where it sits in the supply chain

  • Materials
  • Specialty chemicals
  • Additives, rubber chemicals & plastics

What could go right

  • Consumer-related growth markets (hygiene, water treatment)
  • Proceeds from selling the Envalior stake

What could go wrong

  • European chemical demand weakness
  • Energy cost exposure
  • Net debt reduction tied to Envalior stake sale

Moat: narrow (process know-how, scale). Established specialty-chemical process technology and customer relationships, but commodity-adjacent segments face cyclical pricing.

Headquarters: Cologne, Germany · Founded: 2004 · Employees: 11,709

Named competitors

Lanxess at a glance

Size Lanxess (LXS.DE) is a Germany Materials company (Chemicals: Major Diversified) with a market value of $1.19B, the 133rd largest of 198 Germany companies the cockpit tracks. Shares closed at €12.55 on 18 Nov 2026.

Performance Over six months the shares fell 24.4%, against -31.1% for the median peer and -0.9% for the Germany market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue fell 3.6% over the last twelve months (peer median +4.1%); the operating margin is -0.5% (peer median 12.7%).

Valuation It trades at 0.6× enterprise value to sales against a peer median of 2.4× (2nd cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 5.8 points below its cost of capital (5.5% WACC).

Credit Lanxess has 5 bonds outstanding ($2.55B), rated NR by the agencies and trading like BB- at a weighted spread of 260 bp.

Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026LXS.DE 76Peer median 72
Six months, rebased to 100: Lanxess against the median of its 20 peers (local-currency closes).

Lanxess financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€5.67B€5.67B€6.37B€6.71B€8.09B
Revenue growth—-11%-5%-17%—
Gross profit€1.11B€1.13B€1.30B€1.27B€1.94B
EBITDA€671M€497M€609M€522M€989M
Net income-€662M-€577M-€177M€443M€250M
Free cash flow€118M-€56.0M€158M€464M-€301M
Capital expenditure€326M€319M€320M€326M€407M
Total debt€2.98B€2.53B€3.01B€3.01B€4.25B

Quarterly statements and history in the cockpit →

Lanxess competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%00042060328147636003286032000025854041300779VCT7666300596014680300910JUBLINGREAPRIVISCL214370603360RPEL300641LXS.DE6-month return →1-month return →
Up and to the right = strong over both horizons. Lanxess is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%0×10×20×30×00042060328147636003286032000025854041300779VCT7666JUBLINGREAPRIVISCL214370603360RPEL300641LXS.DERevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Lanxess is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%60328147630025854041301090VCT300910JUBLINGREAPRIVISCL214370603360300641LXS.DEGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Lanxess is the large dot.

Lanxess competitors and peer comparison

Head to head with its named competitors (LXS.DE vs EVK.DE vs CLN.SW vs ALB)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Lanxess LXS.DE$1.19B-24%-4%0%0.6×5.3%
Evonik Industries EVK.DE$11.1B+27%+2%10%1.0×-5.6%
Clariant CLN.SW$4.20B+35%-7%10%1.4×-3.3%
Albemarle ALB$10.1B-49%+24%17%2.1×5.6%
Ashland ASH$3.50B+36%+2%7%2.4×12.7%

How Lanxess compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Lanxess against its 20 peers (data as of 18 Nov 2026)
MeasureLXS.DEPeer medianRank in peer set
1-month return+1.4%-12.1%5th highest of 21
6-month return-24.4%-31.1%10th highest of 21
Distance from 52-week high-43.0%-48.8%10th highest of 21
Revenue growth (TTM)-3.6%+4.1%6th lowest of 21
Operating margin-0.5%12.7%5th lowest of 21
EV / Sales0.6×2.4×2nd cheapest of 21
Growth the price implies (Req g, 7 yrs)5.3%8.5%5th least demanding of 14
Growth delivered (Del g)-1.5%+7.4%lowest of 14
Hurdle (Req g minus delivered)+6.7 pp-1.6 pp6th most demanding of 14
ROIC minus cost of capital-5.8 pp-1.3 pp5th lowest of 21
EV / EBITDA4.7×13.4×2nd cheapest of 9
Net debt / EBITDA3.0×0.5×most indebted of 9
Bond spread260 bpn/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Lanxess LXS.DEGermany$1.19B-24%-4%0%0.6×5.3%-1.5%
Jilin Chemical Fibre Stock 000420.SZChina$1.20B-34%+11%5%2.6×n/an/a
Hubei Jianghan New Materials 603281.SSChina$1.15B-38%+8%17%2.4×3.9%+6.3%
Jinan Acetate Chemical 4763.TWTaiwan$1.14B-5%-24%43%1.9×-20.2%+41.2%
CNSIG Inner Mongolia Chemical Industry 600328.SSChina$1.12B-36%-20%-7%1.7×n/an/a
Shanghai Emperor of Cleaning Hi-Tech 603200.SSChina$1.12B-24%+4%-8%15.2×n/an/a
Jiangsu Shuangxing Color Plastic New Materials 002585.SZChina$1.27B-10%-4%-4%2.0×21.0%+0.2%
Nippon Soda 4041.TJapan$1.29B+11%0%10%1.5×5.2%+1.8%
China Resources Chemical Innovative Materials 301090.SZChina$1.30B-33%+4%1%0.5×20.6%+1.1%
Qingdao Huicheng Environmental Technology 300779.SZChina$1.08B-48%-13%5%10.4×n/an/a
Victrex VCT.LUnited Kingdom$1.06B+46%-1%14%2.8×16.7%+1.9%
Metis TechBio 7666.HKHong Kong$1.05B-64%+6,987%-367%45.2×n/an/a
Rianlon 300596.SZChina$1.35B-15%+11%11%1.8×n/an/a
Hanchem 014680.KSSouth Korea$1.35B-49%+11%17%2.1×5.8%+7.4%
Xinxiang Richful Lube Additive 300910.SZChina$1.36B-33%+12%16%2.4×2.1%+32.5%
Jubilant Ingrevia JUBLINGREA.NSIndia$1.00B-19%+15%10%2.0×28.0%+44.9%
Privi Speciality Chemicals PRIVISCL.NSIndia$1.44B+11%+18%20%5.2×30.6%+15.0%
Caregen 214370.KSSouth Korea$982M-74%-2%20%16.8×36.8%+3.8%
Dalian Bio-Chem 603360.SSChina$971M-54%0%16%5.1×8.5%+18.4%
Raghav Productivity Enhancers RPEL.NSIndia$942M+109%+38%28%27.9×n/an/a
Jiangsu Zhengdan Chemical Industry 300641.SZChina$914M-29%-30%17%2.2×7.1%+11.6%

Lanxess bonds and credit

Lanxess has 5 bonds outstanding with $2.55B face value. The agencies rate it NR; its bonds trade like BB-. Weighted yield 5.71%, a spread of 260 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Lanxess's main competitors?
Named competitors: Evonik Industries (EVK.DE), Clariant (CLN.SW), Albemarle (ALB), Ashland (ASH). The cockpit's measured peer set (industry) also includes Jilin Chemical Fibre Stock (000420.SZ), Hubei Jianghan New Materials (603281.SS), Jinan Acetate Chemical (4763.TW), CNSIG Inner Mongolia Chemical Industry (600328.SS), Shanghai Emperor of Cleaning Hi-Tech (603200.SS), Jiangsu Shuangxing Color Plastic New Materials (002585.SZ).
Is Lanxess expensive compared with its peers?
On ev / sales it trades at 0.6× against a peer median of 2.4×, 2nd cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Lanxess stock performed?
Over six months to 18 Nov 2026 the shares returned -24.4% against -31.1% for the median peer; over one year -23.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.